trending Market Intelligence /marketintelligence/en/news-insights/trending/NXS1hT2VuBAneQCr0-0Mew2 content esgSubNav
In This List

Report: Activist investor pushing for change at Alexion Pharmaceuticals

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Podcast

Street Talk | Episode 99 - Higher rates punish bond portfolios, weigh on bank M&A

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Report: Activist investor pushing for change at Alexion Pharmaceuticals

Elliott Management Corp., a stakeholder in Alexion Pharmaceuticals Inc., is pushing the company to take measures aimed at raising its stock price, The New York Times reported Dec. 7, citing unnamed sources.

The U.S. hedge fund is urging Alexion to put out a more aggressive financial performance guidance or consider strategic options, including a sale of the company.

According to the publication's sources, Elliott Management could initiate a proxy fight to take board seats if the biopharmaceutical company fails to take action.

Following the report, Alexion's stock was up 8.37% to $115.72 as of 2:22 p.m. ET on Dec. 8.